Matinas BioPharma (NYSEAMERICAN:MTNB) is set to release its earnings data before the market opens on Tuesday, August 13th. Analysts expect Matinas BioPharma to post earnings of ($0.04) per share for the quarter.
Matinas BioPharma (NYSEAMERICAN:MTNB) last issued its earnings results on Monday, May 13th. The company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.01).
Shares of Matinas BioPharma stock opened at $0.74 on Tuesday. Matinas BioPharma has a twelve month low of $0.35 and a twelve month high of $1.50.
MTNB has been the subject of several analyst reports. BTIG Research initiated coverage on shares of Matinas BioPharma in a report on Friday, May 17th. They set a “buy” rating and a $5.00 price target for the company. Zacks Investment Research raised shares of Matinas BioPharma from a “sell” rating to a “hold” rating in a report on Wednesday, July 17th. Maxim Group reissued a “buy” rating and set a $5.00 price target on shares of Matinas BioPharma in a report on Thursday, May 16th. Finally, HC Wainwright initiated coverage on shares of Matinas BioPharma in a report on Wednesday, June 26th. They set a “buy” rating and a $4.00 price target for the company. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $4.00.
In related news, Director Adam K. Stern bought 80,000 shares of the company’s stock in a transaction on Friday, May 31st. The stock was bought at an average cost of $0.94 per share, with a total value of $75,200.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last ninety days, insiders acquired 187,487 shares of company stock valued at $167,290.
About Matinas BioPharma
Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.
Featured Story: What does it mean to hold a stock in street name?
Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.